Cost-effectiveness analysis of voriconazole versus amphotericin B in the treatment of invasive aspergillosis in Spain

被引：2
|
作者：
Grau, S
Mateu-de, AJ
Soto, J
Muñoz, M
Salas, E
机构：
[1] Univ Autonoma Barcelona, Hosp Mar, Dept Med, E-08003 Barcelona, Spain
[2] Pfizer SA, Madrid, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61912-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：750 / 751
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia
    Al-Badriyeh, Daoud
    Liew, Danny
    Stewart, Kay
    Kong, David C. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (01) : 197 - 208
  • [32] COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASE IN CHINA
    Tang, W.
    Shao, R.
    VALUE IN HEALTH, 2019, 22 : S650 - S650
  • [33] Superiority of voriconazole over amphotericin B in the treatment of invasive Aspergillosis after heart transplantation
    Wieland, T
    Liebold, A
    Jagiello, P
    Retzl, G
    Birnbaum, DE
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (01): : 102 - 104
  • [34] Treatment Strategies for Invasive Aspergillosis in Neutropenic Patients: Voriconazole or Liposomal Amphotericin-B?
    Pagano, L.
    Valentini, C. G.
    Fianchi, L.
    Caira, M.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 5 - 8
  • [35] Evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany (vol 9, pg 12, 2006)
    Jansen, Jeroen P.
    Kern, Winfried V.
    Cornely, Oliver A.
    Karthaus, Meinolf
    Ruhnke, Markus
    Ullmann, Andrew J.
    Resch, Ansgar
    VALUE IN HEALTH, 2006, 9 (05) : 359 - 359
  • [36] Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico
    Morfin-Otero, Rayo
    Alvarado-Ibarra, Martha
    Rodriguez-Noriega, Eduardo
    Resendiz-Sanchez, Jesus
    Patel, Dipen A.
    Stephens, Jennifer M.
    Di Fusco, Manuela
    Mendoza, Carlos F.
    Charbonneau, Claudie
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 511 - 520
  • [37] COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN BRAZIL
    Xue, M.
    Gao, X.
    Ferreira, C. N.
    Stephens, J. M.
    Haider, S.
    Figueiredo Valente, M. L.
    Charbonneau, C.
    VALUE IN HEALTH, 2015, 18 (07) : A820 - A820
  • [38] Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis
    Neoh, Chin Fen
    Liew, Danny
    Slavin, Monica
    Marriott, Debbie
    Chen, Sharon C. -A.
    Morrissey, Orla
    Stewart, Kay
    Kong, David C. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1906 - 1915
  • [39] COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF PAEDIATRIC PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS
    Odeyemi, A.
    Hart, W. M.
    Odeyemi, I. I.
    Musingarimi, P.
    VALUE IN HEALTH, 2010, 13 (03) : A189 - A189
  • [40] COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B AND CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN LEBANON
    Helou, G.
    Gao, C.
    Xue, M.
    Tarcha, N.
    Charbonneau, C.
    VALUE IN HEALTH, 2016, 19 (07) : A583 - A584
12345